<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531124</url>
  </required_header>
  <id_info>
    <org_study_id>Huashan cardiology</org_study_id>
    <nct_id>NCT04531124</nct_id>
  </id_info>
  <brief_title>Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives</brief_title>
  <official_title>Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives：a Multicenter Prospective Cohort Study （UPDATE-cohort）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this clinical trial is designed to study the cardiovascular and renal outcomes of&#xD;
      hypertensives after an integrated management of blood pressure and other cardiometabolic&#xD;
      risks. it is a multicenter prospective cohort study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>complex outcome</measure>
    <time_frame>follow-up 1 year</time_frame>
    <description>number of participants with 3P-MACE events(cardiovascular deaths, non-fatal myocardial infarction, non-fatal stroke)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>coronary angioplasty</measure>
    <time_frame>follow-up 1 year</time_frame>
    <description>number of participants with coronary angioplasty</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute renal failure</measure>
    <time_frame>follow-up 1 year</time_frame>
    <description>number of participants with acute renal failure(eGFR decreases by 50% or &lt;15ml/min/1.73m2, dialysis or renal death)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute heart failure</measure>
    <time_frame>follow-up 1 year</time_frame>
    <description>number of participants with acute heart failure(non-scheduled hospitalizations due to heart failure or required intravenous medication)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Hypertension</condition>
  <condition>Renal Disease</condition>
  <arm_group>
    <arm_group_label>control group without an integrated management</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>observational group with an integrated management</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>integrated management</intervention_name>
    <description>establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients</description>
    <arm_group_label>observational group with an integrated management</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        outpatients with hypertension in different levels of hospitals in Shanghai, China&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatients from departments of Cardiology, Endocrinology, Nephrology, Neurology,&#xD;
             Geriatrics or General Internal Medicine.&#xD;
&#xD;
          2. Diagnosed as hypertension. Diagnostic criteria: 1)The office BP measured at the day of&#xD;
             visit and at least one time before that day were above the cut-off values ( ≥140 mmHg&#xD;
             SBP and/or ≥90 mmHg DBP); 2)for patients with normal BP at the day of visit, they&#xD;
             should have already been given pre-treatment with antihypertensive drugs ≥ 2 weeks.&#xD;
&#xD;
          3. Voluntary participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients aged&lt; 18 years old.&#xD;
&#xD;
          2. Patients without a definite diagnosis of hypertension(for instance, if the patient has&#xD;
             been taking antihypertensive drugs irregularly, it is difficult to confirm the&#xD;
             diagnosis of hypertension).&#xD;
&#xD;
          3. Patients with a definite diagnosis of secondary hypertension.&#xD;
&#xD;
          4. Patients are diagnosed dyslipidemia with clear cause, such as nephrotic syndrome,&#xD;
             severe hypothyroidism, terminal stage of malignancy, etc.&#xD;
&#xD;
          5. Patients are diagnosed end-stage renal disease, hemodialysis, and peritoneal dialysis&#xD;
             patients.&#xD;
&#xD;
          6. Patients diagnosed with mental abnormalities who are unable to complete the&#xD;
             questionnaire.&#xD;
&#xD;
          7. Patients have once participated in this research during this study cycle(to avoid&#xD;
             repeated participation).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yong li, professor</last_name>
    <phone>+86 13801753494</phone>
    <phone_ext>china shanghai</phone_ext>
    <email>liyong606@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiufang gao, associate professor</last_name>
    <phone>+86 13788908071</phone>
    <email>sophiakao@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HuashanH</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 15, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Yong Li</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

